Navigation Links
Dr. Daniel Von Hoff presented with top genomics award from Scripps
Date:3/17/2011

LA JOLLA, Calif. March 17, 2011 Dr. Daniel Von Hoff was presented this month with the Scripps Genomic Medicine Award for his "pioneering efforts" in sequencing, or spelling out, the DNA of patients with rare cancers.

Dr. Von Hoff's research and clinical work advances the art of using the fully sequenced genomes of cancer patients, spelling out all 3 billion letters of their DNA, to help determine the best course of treatment.

"I am extremely humbled and honored to receive this award on behalf of all the institutes, medical centers and oncology groups I'm associated with. Through this work, we are trying to improve things for every patient," said Dr. Von Hoff, who holds the titles of Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen); Professor of Medicine at both Mayo Clinic and at the University of Arizona College of Medicine; and Chief Scientific Officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and at US Oncology.

Dr. Von Hoff is recognized as one of the world's leading authorities on pancreatic cancer. Some of his most recent work involves the comparative analysis of the fully sequenced genomes of patients with rare cancers and with triple-negative breast cancer, identifying the mutations in the DNA of the patients' tumors and using that information to help guide future treatment of this rare and challenging disease.

Dr. Eric J. Topol, Director of the Scripps Translational Science Institute (STSI), presented the Genomic Medicine award to Dr. Von Hoff, citing his "pioneering efforts" in whole genome sequencing as a tool for matching a patient's genetic makeup with treatments that will provide the best quality of life.

"Dr. Von Hoff's work represents the future of medicine, in which information gleaned from the complex assemblage of an individual's DNA can be used to target deadly tumors, even among patients with rare cancers," said Dr. Topol, who also is Chief Academic Officer of Scripps Health, and Professor of Translational Genomics at the Scripps Research Institute.

The award was presented to Dr. Von Hoff during the Future of Genomic Medicine IV conference, March 3-4, at the Robert Paine Scripps Forum for Science, Society and the Environment, Samuel H. Scripps Auditorium, in La Jolla, Calif.

Physicians, health care professional, human geneticists, genomic scientists and researchers attended the conference. This fourth installment of the Future of Genomic Medicine conference focused on the extraordinary advances occurring in the field, including whole genome and exome sequencing, new gene expression tests for routine medical practice, and consumer genomics. The overarching goal of the annual conference is to spearhead efforts to change medicine by using genomics.

Like all who work with Dr. Von Hoff, the STSI aims to replace the status quo of one-size-fits-all-medicine with individualized health care that is based on the known genetic factors influencing health and disease.

Under the leadership of Dr. Topol, one of the world's premier cardiologists and physician/scientists, STSI has created major programs in both research and education-training that bridge science with medicine, and academia with industry.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Cell biologist Daniel Gottschling elected to American Academy of Arts & Sciences
2. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
3. Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010
4. LungPoint system results presented at American Thoracic Society 2010 International Conference
5. Selected highlights of the research being presented at the Experimental Biology 2010 meeting
6. Latest research on GI health presented at DDW 2010
7. Early detection of lung cancer: New data presented at multidisciplinary meeting
8. IADR Wilmer Souder Award presented to University of Colorado professor
9. World Energy Outlook to be presented at Rice University Dec. 9
10. New cardiology research presented at CHEST 2008
11. DOE JGI Genomics of Energy & Environment Meeting set for March 22-24, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading producer ... Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 ... form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface ...
Breaking Biology Technology: